Matthew Caufield

Stock Analyst at HC Wainwright & Co.

(2.04)
# 2,991
Out of 4,914 analysts
115
Total ratings
41.18%
Success rate
-8.64%
Average return

Stocks Rated by Matthew Caufield

LENZ Therapeutics
Jul 28, 2025
Maintains: Buy
Price Target: $38$48
Current: $31.51
Upside: +52.33%
DiaMedica Therapeutics
Jul 18, 2025
Maintains: Buy
Price Target: $10$12
Current: $5.06
Upside: +137.15%
Opus Genetics
Jun 27, 2025
Reiterates: Buy
Price Target: $8
Current: $1.20
Upside: +566.67%
Ardelyx
Jun 18, 2025
Assumes: Buy
Price Target: $10
Current: $4.28
Upside: +133.64%
Mineralys Therapeutics
Jun 17, 2025
Reiterates: Buy
Price Target: $42
Current: $13.60
Upside: +208.82%
Lyra Therapeutics
Jun 10, 2025
Maintains: Neutral
Price Target: $2$16
Current: $7.80
Upside: +105.13%
Phathom Pharmaceuticals
Jun 9, 2025
Reiterates: Buy
Price Target: $20
Current: $8.80
Upside: +127.27%
Akebia Therapeutics
Jun 4, 2025
Assumes: Buy
Price Target: $8
Current: $3.59
Upside: +122.84%
Tarsus Pharmaceuticals
May 27, 2025
Assumes: Buy
Price Target: $72
Current: $41.75
Upside: +72.46%
Aldeyra Therapeutics
May 19, 2025
Reiterates: Buy
Price Target: $10
Current: $5.32
Upside: +87.97%
Reiterates: Buy
Price Target: $30
Current: $16.45
Upside: +82.37%
Reiterates: Buy
Price Target: $30
Current: $2.65
Upside: +1,032.08%
Reiterates: Buy
Price Target: $32
Current: $9.31
Upside: +243.72%
Reiterates: Buy
Price Target: $10
Current: $1.08
Upside: +825.93%
Reiterates: Buy
Price Target: $12
Current: $0.66
Upside: +1,729.27%
Reiterates: Neutral
Price Target: $2
Current: $2.14
Upside: -6.54%
Reiterates: Neutral
Price Target: $3
Current: $8.24
Upside: -63.59%
Downgrades: Neutral
Price Target: $12$2
Current: $3.41
Upside: -41.35%
Reiterates: Buy
Price Target: $36
Current: $4.64
Upside: +675.86%
Reiterates: Buy
Price Target: $28
Current: $316.64
Upside: -91.16%